Prosecution Insights
Last updated: April 19, 2026
Application No. 18/776,139

HEART VALVE PROSTHESIS

Non-Final OA §102
Filed
Jul 17, 2024
Examiner
NGUYEN, VI X
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Jc Medical Inc.
OA Round
1 (Non-Final)
86%
Grant Probability
Favorable
1-2
OA Rounds
3y 5m
To Grant
99%
With Interview

Examiner Intelligence

Grants 86% — above average
86%
Career Allow Rate
983 granted / 1145 resolved
+15.9% vs TC avg
Moderate +13% lift
Without
With
+13.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
29 currently pending
Career history
1174
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
36.9%
-3.1% vs TC avg
§102
40.1%
+0.1% vs TC avg
§112
11.0%
-29.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1145 resolved cases

Office Action

§102
DETAILED ACTION Election/Restrictions Applicant’s election without traverse of Species 1, claims 1-13 in the reply filed on 12/12/2025 is acknowledged. Claims 14-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 12/12/2025. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-8, 10-13 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Tuval et al U.S 2009/0240320. Claim 1: Tuval et al disclose a valve prosthesis support frame (see fig. 1; the inner support structure/support frame at 12, see paragraph 598) comprising a plurality of cells that form a bottom row of cells, a middle row of cells, and a top row of cells (see fig. 1 with annotated below), the bottom row of cells defining a bottom edge of the support frame, the middle row of cells being circumferentially offset from the bottom row of cells, the top row of cells defining a top edge of the frame having three sets of cells that are circumferentially spaced apart from each other by at least one cell (it is noted that a plurality of major peak portions comprises three pairs of diamond-shaped cells i.e., asymmetric hourglass shape, see paragraph 27 and the prosthesis including a valve prosthesis support, which valve prosthesis support includes a support structure including exactly three engagement arms that meet one another at three respective junctures, and the engagement arms are shaped so as define three peak complexes at the three respective junctures, and three trough complexes, each of which is between two of the peak complexes, see paragraph 117 which represent the top row having 3 sets of cells), the top row of cells forming a plurality of major peak portions along the top edge of the frame the middle row of cells defining at least one minor peak portion disposed longitudinally intermediate the bottom edge and the plurality of major peak portions and being configured to allow access to and prevent obstruction to an ostia of a patient (it is noted that valve prosthesis 10 is configured such that when engagement arms 22 are placed properly within aortic sinuses 164, outer strut supports 20 are aligned with commissures 170 (see, for example, FIG. 8A), thus preventing any possible obstruction of coronary ostia 116 by valve prosthesis 10. At this point in the implantation procedure, the distal end of valve prosthesis 10 is free of overtube or trocar 150, and the proximal end of prosthesis 10 remains in overtube or trocar 150 (see figures 6a,b, paragraph 633). PNG media_image1.png 559 678 media_image1.png Greyscale Claims 2-3: Tuval et al disclose wherein the three sets of cells are circumferentially spaced apart from each other by two cells (see paragraph 117)., wherein the top row of cells comprises three sets of three cells that are circumferentially spaced apart from each other by at least one cell (see fig. 1 above). Claims 4-5: Tuval et al disclose wherein each cell of the plurality of cells has a uniform shape and size (see paragraph 71)., wherein the plurality of major peak portions comprises three pairs of diamond-shaped cells (asymmetric hourglass shape, see paragraph27). Claims 6-7: Tuval et al disclose wherein each major peak of the plurality of major peak portions has a longitudinal height defined as a height of two cells of the plurality of cells., wherein each minor peak of the at least one minor peak portion has a longitudinal height defined as a height of one and a half cells of the plurality of cells (it is noted that fig. 4c has different heights of membrane that is varies between the major peaks and the minor peals of the support frame, see paragraph 623). Claims 8, 10: Tuval et al disclose wherein the at least one minor peak portion comprises three minor peaks that are each radially intermediate respective major peaks of the plurality of major peak portions (see annotated fig. 1 above; wherein the support frame comprises a shape-memory material (see paragraph 603). Claims 11-13: Tuval et al disclose wherein the support frame comprises a laser-cut tubular mesh (the area 206, fig. 12c, see paragraph 660)., wherein the support frame is self- expanding (see paragraph 40)., further comprising a plurality of hooks (move barb 120, fig. 2b) extending from the bottom edge of the support frame. Allowable Subject Matter Claim 9 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim 9: the prior arts fail to disclose or reasonably suggest the claimed including the plurality of major peak portions that has three major peaks and one minor peak portion that comprises three minor peaks that are each interposed between major peaks of the plurality of major peak portions. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to VI X NGUYEN whose telephone number is (571)272-4699. The examiner can normally be reached Monday-Friday (6:30-4:30). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached at 571-272-4695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /VI X NGUYEN/Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Jul 17, 2024
Application Filed
Feb 05, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582750
METHOD FOR PRODUCING TRANSPLANTABLE ORAL MUCOSA TISSUE
2y 5m to grant Granted Mar 24, 2026
Patent 12575848
Ultrasonic Surgical Tool System Including a Tip Capable of Simultaneous Longitudinal and Torsional Movement and a Console Capable of Applying a Drive Signal to the Tip so the Tip Engages in Substantially Torsional Oscillations
2y 5m to grant Granted Mar 17, 2026
Patent 12569657
SYSTEMS AND METHODS FOR THE TREATMENT AND PREVENTION OF FEMALE PELVIC DYSFUNCTION
2y 5m to grant Granted Mar 10, 2026
Patent 12569234
DEVICES AND METHODS FOR OCCLUDING ABNORMAL OPENINGS IN A PATIENT'S VASCULATURE
2y 5m to grant Granted Mar 10, 2026
Patent 12564656
SPRAYABLE TISSUE ADHESIVE WITH BIODEGRADATION FOR WOUND TREATMENT
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
86%
Grant Probability
99%
With Interview (+13.3%)
3y 5m
Median Time to Grant
Low
PTA Risk
Based on 1145 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month